Skip to content

News

Revolutionary study offers hope in combating coronary heart disease.

Groundbreaking research by Kaiser Permanente paves the way for a personalised, predictive approach to combating coronary heart disease, potentially saving millions of lives with the innovative CARDIO inCode-Score®. In a groundbreaking study published in the American Journal of Preventive Cardiology, researchers have unlocked a promising avenue in the fight against the global scourge of coronary heart disease (CHD). Conducted by
Read More >

New NICE Guidance for Ovarian Cancer

Surveillance using the ROCA test is now an option for individuals at high risk of ovarian cancer Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk of ovarian cancer (“OC”), announces that its Risk of Ovarian Cancer Algorithm (“ROCA”) test, has received a National Institute for Health and Care
Read More >
CARDIO inCode® study on risk of incident Coronary Heart Disease presented at European Society of Cardiology in Amsterdam

CARDIO inCode® study on risk of incident Coronary Heart Disease presented at European Society of Cardiology in Amsterdam

Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease, announces the presentation by Kaiser Permanente, US on the ‘Utility of the CARDIO inCode-Score® CHD polygenic risk score for incident coronary heart disease interplay with lifestyle in a multi-ethnic cohort of more than 60,000 individuals’. The presentation was made at the Annual Meeting of
Read More >
Premarket Notification 510(k) medical device filing for CARDIO inCode-Score (CIC-SCORE)  

Premarket Notification 510(k) medical device filing for CARDIO inCode-Score (CIC-SCORE)  

Premarket Notification 510(k) medical device filing for CARDIO inCode-Score (CIC-SCORE)   510(k) approval will enable US expansion and commercial distribution of CARDIO inCode-Score medical device   Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease (“CVD”), announces it has filed its Premarket Notification (510k) with the Food and Drug Administration (FDA) to expand its
Read More >
Collaboration with US healthcare provider for CARDIO inCode-Score® testing

Collaboration with US healthcare provider for CARDIO inCode-Score® testing

MedStar to start clinical use of CARDIO inCode-Score® polygenic testing to prevent cardiovascular disease. Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with MedStar Health (“MedStar”), a ten-hospital health system in the Washington, D.C. area, to use its CARDIO inCode-Score® (“CIC-SCORE”) test in primary care for the risk
Read More >
Marketing & Business Development Manager

Marketing & Business Development Manager

MARKETING & BUSINESS DEVELOPMENT MANAGER-HYBRID ROLE-BARCELONA SPAIN-FULL TIME-UP TO € 65-75k + Bonus + Benefits (negotiable) We are a leading genetic testing organisation seeking an experienced Marketing & Business Develpment Manager   to join our team in GENinCode SLU (based in Barcelona) on a full time basis, with flexible working arrangements available. Working closely with the Group COO, the Marketing &
Read More >

Announcement of collaboration with University Clinic Dresden, Germany for the implementation of Lipid inCode® testing

University Clinic in Dresden, Germany to commence testing Lipid inCode® polygenic testing to prevent Cardiovascular Disease Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces today its collaboration with the University Clinic Dresden, Department of Internal Medicine and Department of Human Genetics, based in Dresden, Germany to use its Lipid inCode®
Read More >

NHS accelerates implementation of LIPID inCode® testing of patients suffering with hypercholesterolemia and familial hypercholesterolemia

NHS earmarks budget to expand GENinCode’s LIPID inCode® polygenic testing to prevent Cardiovascular Disease Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease, announces the expansion of its collaboration with the Academic Health Science Network for the North East and North Cumbria (“AHSN NENC”) to use the LIPID inCode® polygenic test in Primary
Read More >

CLINICAL SCIENTIST – GENETIC TESTING, BIOTECH

FULL TIME/PART TIME CLINICAL SCIENTIST  – GENETIC TESTING, IN-VITRO DIAGNOSTIC. SALARY NEG DEPENDANT UPON EXPERIENCE + BENEFITS We are a leading Genetic Testing organisation seeking an experienced Clinical Scientist  to join our team in Barcelona on a permanent, full time/part time basis, with flexible working patterns available. GENinCode is a Cutting-edge Biotech company specialized in Predictive  Genetics with a portfolio focused
Read More >
Premarket Notification 510(k) medical device filing for CARDIO inCode-Score (CIC-SCORE)  

US CPT PLA Code Granted for CARDIO inCode-SCORE (CIC-SCORE) _ CPT PLA Code is key component for reimbursement from private medical insurance and Medicare

Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease (“CVD”), announces the Amercian Medical Asscoiation (AMA) grant of a Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for its CARDIO inCode-SCORE (“CIC-SCORE”) polygenic test for the risk assessment of Coronary Heart Disease. The new code 0401U, has been approved and published by
Read More >